

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

In re Sitagliptin Phosphate ('708 & '921)  
Patent Litigation

C.A. No. 19-md-2902-RGA

MERCK SHARP & DOHME CORP.,

*Plaintiff,*

v.

C.A. No. 21-315-RGA

ZYDUS WORLDWIDE DMCC, ZYDUS  
PHARMACEUTICALS (USA) INC. and  
CADILA HEALTHCARE LTD.,

*Defendants.*

MERCK SHARP & DOHME CORP.,

*Plaintiff,*

C.A. No. 22-444-RGA

MANKIND PHARMA LTD. and  
LIFESTAR PHARMA LLC,

*Defendants.*

**ORDER GRANTING UNOPPOSED MOTION TO SUBSTITUTE PLAINTIFF  
AND AMEND CASE CAPTION**

Having considered the Motion to Substitute Plaintiff and Amend Case Caption, and  
pursuant to Fed. R. Civ. P. 17 and 25(c), IT IS HEREBY ORDERED that:

1. Merck Sharp & Dohme LLC is substituted for Merck Sharp & Dohme Corp. as  
the plaintiff in this action.

2. The case captions for these actions shall be amended to remove Merck Sharp & Dohme Corp., and add Merck Sharp & Dohme LLC.

The new caption for the Zydus action (C.A. 21-315-RGA) shall be as follows:

MERCK SHARP & DOHME LLC,

*Plaintiff,*

v.

C.A. No. 21-315-RGA

ZYDUS WORLDWIDE DMCC, ZYDUS PHARMACEUTICALS (USA) INC. and CADILA HEALTHCARE LTD.,

*Defendants.*

The new caption for the Mankind action (C.A. 22-444-RGA) shall be as follows:

MERCK SHARP & DOHME LLC,

*Plaintiff,*

C.A. No. 22-444-RGA

MANKIND PHARMA LTD. and LIFESTAR PHARMA LLC,

*Defendants.*

June 21, 2022  
DATE

/s/ Richard G. Andrews  
UNITED STATES DISTRICT JUDGE